Embryonic stem cells (ESCs) were first isolated from mouse embryos more than 30 years ago. They have proven invaluable not only in generating genetically modified mice that allow for analysis of gene function in tissue development and homeostasis but also as models for genetic disease. In addition, ESCs in vitro are finding inroads in pharmaceutical and toxicological testing, including the identification of teratogenic compounds. Here, we describe the use of a bone morphogenetic protein (Bmp)-reporter ESC line, isolated from a well-characterized transgenic mouse line, as a new tool for the identification of chemical teratogens. The Bmp-mediated expression of the green fluorescent protein enabled the quantification of dose-and time-dependent effects of valproic acid as well as retinoic acid. Significant effects were detectable at concentrations that were comparable to the ones observed in the classical embryonic stem cell test, despite the fact that the reporter gene is expressed in distinct cell types, including endothelial and endodermal cells. Thus these cells provide a valuable new tool for the identification and characterization of relevant mechanisms of embryonic toxicity.
Multiple dynamic processes regulate cell differentiation and organ morphogenesis during embryonic development. How these complex processes are affected by toxic reagents is still largely unknown. Therefore, the assessment of chemicals that might pose a serious hazard to human (developmental) health mainly relies on the use of experimental animals. Recent changes in legislation restricting the use of experimental animals, in particular in Europe, has initiated research into alternative approaches to address developmental toxicity by taking advantage of the underlying molecular mechanisms (Whelan and Andersen, 2013) . Two recent contributions to this kind of research include (1) improvements in bioinformatics and analytics that allow comprehensive spatial-temporal analysis of cellular responses on the molecular level (Sturla et al., 2014) and (2) new cell and embryo culture techniques that provide relevant mechanistic information . Nevertheless, a comprehensive and predictive testing strategy for embryotoxicity is not anticipated in the near future (Adler et al., 2011) .
Another trend in understanding developmental processes utilizes genetically modified animals and derived cell lines thereof. Such systems have the advantage that direct comparison of in vitro and in vivo data is possible and the influence of chromosomal integration sites on the biology are either known or can be excluded (Wilson et al., 1990) . Signaling pathways modulated by toxic reagents are often in the focus of studies using such cell lines for risk assessment and mechanistic insights (Boverhof et al., 2011) . The first steps in embryogenesisincluding germ layer formation during gastrulation, axis specification, proliferation, differentiation, cell death, and cell migration-are controlled by rather few highly conserved signaling pathways (Loebel et al., 2003) . Among these the bone morphogenetic protein (Bmp) signaling pathway is of particular importance. This pathway, as part of the transforming growth factor (Tgf) b signaling pathway, is evolutionarily highly conserved both in structure and function, and is crucial during embryonic development in many vertebrate and invertebrate species (Bier, 2011) . The Bmp protein family consists of more than 20 secreted molecules in mammals that induce the assembly of heteromeric receptor complexes of type I and type II transmembrane serine/ threonine kinases. The type II receptor kinase activates the type I receptor kinase, which subsequently phosphorylates receptorSmad proteins (R-Smads, Smad 1, 5, 8) at its C-terminus. This phosphorylation then stimulates the binding of R-Smad to a common cofactor, Smad 4, leading to the translocation of the complex into the nucleus. The transcriptional regulation of target genes is facilitated through the binding of the complex to Bmp response elements (BREs) (reviewed in Weiss and Attisano, 2013) .
Here, we describe a new embryonic stem cell (ESC) line that has been isolated from a transgenic mouse line carrying a BRE promoter (BRE-ESC) upstream of an enhanced green fluorescent protein (EGFP). In vivo, EGFP expression was detected in the extra-embryonic mesoderm at day 7.5, followed by expression in the developing heart, blood vessels as well as in kidney, bone, liver, pancreas, lung, and hair follicles at later stages. Although some known Bmp activity centers did not express EGFP, the overall reporter gene activity correlated well with known biological activities of Bmp signals (Monteiro et al., 2008) . The ESCs derived from these mice could then in principle report Bmp signaling faithfully in culture at different stages of differentiation using the standard procedure developed during the validation of the embryonic stem cell test (EST, Seiler and Spielmann, 2011) . The dependence of differentiation on Bmp signaling made the BRE-ESCs a possibly suitable tool to assess inhibitory effects of substances and might broaden the predictivity of the EST. Our results indicate that the in vitro reporter gene activity at least partially recapitulates the in vivo expression pattern and might serve as a predictive marker for teratogenic activity, providing a new tool for the identification of potentially teratogenic substances.
MATERIALS AND METHODS
ESC culture. The BRE-ESCs were derived from the transgenic reporter mice as previously described (Doetschmann et al., 1985) . Experiments were performed in agreement with the German law on the use of laboratory animals as well as biosafety (S1) and institutional guidelines of the Max Planck society. The use of animals was approved by "Regierungsprä sidium Freiburg (Freiburg regional council)" and the animal welfare office of the Max Planck Institue of Immunobiology and Epigenetics, Freiburg, Germany (KE-2iTO-6). BRE-ESCs were routinely passaged every 2-3 days as described elsewhere (Seiler and Spielmann, 2011) with minor changes. The culture media contained high glucose (4.5 g glucose/l) DMEM (Dulbecco's Modified Eagle's Medium; Gibco Life Technologies, Karlsruhe, Germany), 15% fetal calf serum (Gibco), 2 mM glutamine (Gibco), antibiotics (50 U/ml penicillin and 50 mg/ml streptomycin; Gibco), 1% nonessential amino acids (Gibco) and 0.1 mM b-mercaptoethanol (Sigma, Deisenhofen, Germany). During the routine maintenance passage the cells were kept in 1mM PD0325901, 3mM CHIR99021 media and 1000 U/ml murine leukemia inhibitory factor (Chemicon, Hofheim, Germany) (Ying et al., 2008) .
Differentiation protocol. Hanging drop culture was performed as previously described (Seiler and Spielmann, 2011) . In brief, a cell suspension of 0.5 Â 10 5 cells/ml was prepared in culture media without LIF, CHIR99021, and PD0325901. Twenty-microliter drops were made on the lid of a 10 cm cell culture dish and incubated for 3 days at 37 C and 5% CO 2 . After 3 days, embryoid bodies (EBs)
were transferred into suspension culture for 2 days and then cultivated on cell culture dishes for 2-7 days. For subsequent analysis of differentiation into cardiomyocytes single EBs were transferred into 24-well plates on day 5, for qPCR, EGFP-Assay, and fluorescence activated cell sorting (FACS) analysis 25 EBs each were cultured on 6-well plates from day 5 onwards.
quantitiative PCR.(qPCR). Total RNA was extracted using Trizol (Life Technologies) according to the supplier information. Total RNA extracts were resuspended in 45 ml water and subsequently 5 ml 10Â DNase Buffer and 1 ml DNase (NEB, England) were added. After 30 min at 37 C, the reaction was stopped on ice, purified using phenol/chloroform (Roth, Germany) and precipitated with 100% ethanol and sodium acetate (3 M). cDNA was generated from 2 mg total RNA using HighCapacity cDNA Reverse Transcription Kit (Life Technologies) according to the information provided by the manufacture. cDNAs were diluted 1:10 in water and 1 ml was used for each qPCR reaction on a 7500 Fast RealTime PCR System (Life Technologies). PCR primer sequences are listed in Table 1 . Gene expression were standardized against Gapdh and normalized against the appropriate control. Standard deviation (SD) was calculated from triplicates with differences > 3 Â SD were considered statistically significant.
Western blot. Samples were taken at indicated time points. Cells were lysed in lysis buffer [20mM Tris, 138 mM NaCl, 5% glycerin, 4 mM ethylenediaminetetraacetic acid (EDTA), 1% Triton X-100, 5 mM b-mercaptoethanol supplemented with 1 Â protease inhibitor mix (Roche, Germany), and 0.1 mM sodium orthovanadate] for 10 min. After centrifugation, the protein concentration was determined using the bicinchoninic acid (BCA) assay (ThermoScientific) according to manufacturer's protocol. Forty micrograms of protein lysate was separated on a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred on a nitrocellulose membrane (BioRad), after blocking the membrane for 1 h in 5% milk powder in tris-buffered saline with 0.05% Tween 20 (TBST), the primary antibody incubation was performed in blocking solution over night at 4 C. The antibodies were diluted at 1:500 for anti-Oct4 (sc-9001), anti-Gata4 (sc-9053), and anti-Brachyury (sc-17743). Anti-EGFP (ab13970; Abcam, England), anti-Alcam (AF1172, R&D Systems), and antiTubulin (Abcam, England) were diluted 1:2000, anti-pSmad1 (D40B7, Cell signaling) 1:1000. The appropriate secondary antibody coupled to horseradish peroxidase (Dianova, Hamburg) was diluted 1:10 000, incubated for 1 h at room temperature and detected with SuperSignal West Pico Chemiluminescent Substrate (ThermoScientific) with a ChemiDocs XRS (BioRad).
Mammalian Protein extraction Reagent (ThermoScientific) for 2 h at room temperature or overnight at 4 C. The lysates was centrifuged to remove cell debris and 50 ml of the lysate were transferred into a 96-well plate. The EGFP amount was measured with a Tecan Infinite M2000 plate reader (Tecan Group Ltd, Switzerland) with an excitation wavelength of 485 nm and an emission wavelength of 525 nm. Subsequently, the protein amount in the lysate was determined with a Nano-Drop 1000 (PeqLab Biotechnology GMBH, Germany) using the absorption or optical density (OD) at 280 nm (OD 280 ). After substracting the blank values, the EGFP values were standardized against the protein amount and normalized against the appropriate control. SD was calculated from triplicates with differences > 3 Â SD were considered statistically significant. The Cell Titer Blue assay (CTB; Promega) was performed as described in the protocol provided by the manufacturer. One milliliter of CTB in media (1:10) was used per 6-well for 1 h. Triplicates were sampled (100 ml) and measured with a Tecan Infinite M2000 plate reader, excitation wavelength 560 nm, and emission wavelength 590 nm.
FACS. EBs were incubated with TrypLE Express (Life Technologies) and EDTA (PAN, Germany) for 15 min at 37 C.
Afterwards a single cell suspension was created by vigorously pipetting the cell suspension with FACS buffer (PBS with 5% FCS and 1% EDTA) and filtered through falcon tubes with cell strainer caps (Fisher Scientific). Cell suspension was stained using the Live/Dead fixable near infrared staining Kit (1:1000, Life Technologies) and anti-CD31-BV421 (1:100, 390, BioLegend) for 30 min at room temperature. The samples were fixed with CellFix (BD Biosciences) and stored at 4 C until FACS analysis with a FACS Aria III (BD Biosciences). The evaluation was performed using FlowJo (Tree Star).
Immunofluorescence. For immunofluorescence studies, EBs were seeded on cover dishes. On day 10 or 12, Dil acetylated low density lipoproteins (DiI-Ac-LDL) was applied to the EBs for 4 h at 37 C and 5% CO 2. Then, EBs were treated with 4% paraformaldehyde for 20 min and 0.5% Triton-X-100 for 10 min. Primary antibodies were incubated for 90 min at room temperature: CD31 
RESULTS

Characterization of Differentiation of BRE-ESCs
For efficient differentiation, we used a standard procedure developed in the frame of the validation of the EST (Seiler and Spielmann, 2011) . Applying this protocol, we tested the differentiation potential of the BRE-ESCs and analyzed changes in EGFP expression by fluorescence microscopy (Fig. 1A ). Low levels of EGFP expression were already detectable in BRE-ESCs before induction of differentiation, indicating some Bmp signaling activity in the pluripotent ESC culture. After 4 days of EB formation, the expression of EGFP decreased with some cells at the outer layers of EBs still expressing EGFP. Upon stimulation of EB outgrowth, and subsequent to plating the EBs on cell culture dishes, the number of cells expressing EGFP increased, with more EGFP-positive cells detectable in the leading edge of the EB outgrowth (Fig. 1A , d6-d12). During the subsequent days of differentiation, EGFP expression continued to increase and morphologically distinct EGFP-positive cell populations became detectable (Fig. 1A , d10 and d12). At day 10 of differentiation, some EGFP-positive cells were associated with beating cardiomyocytes without displaying any contracting activity themselves. Another distinct EGFP-positive cell population developed into net-like structures that became visible at day 10-12 of differentiation. To verify the differentiation potential and to analyze the differentiation kinetics of the BRE-ESCs in more detail, we performed qPCR and Western blot analysis of marker genes for pluripotency (Oct4), mesoderm induction (Brachyury), and cardiomyocyte differentiation (Gata4, Alcam, alpha Myosin heavy chain [aMhc]) ( Fig. 1B and 1C ). As expected Oct4 protein as well as transcript levels decreased during the differentiation process. Brachyury, a marker for panmesodermal cells, became detectable on the protein as well as transcript level on day 5 of differentiation. The initial decrease in the Brachyury transcription expression level is probably due to the fact that the BRE-ESCs were kept under so-called 2i (2 inhibitor) conditions (Ying et al., 2008) during routine cell culture. Brachyury is a well-known Wnt target gene and the 2i media includes the Gsk3b inhibitor CHIR99021 that mimics Wnt signaling activity (Arnold et al., 2000; Bain et al., 2007) . The transcription of the mesodermal markers concurred with mesoderm induction although the protein levels displayed the expected delay. Gata4, a marker for cardiomyocyte precursors, is also transcriptionally induced between day 3 and 5 of differentiation, but the protein can first be detected on day 7. Similarly, the expression of aMhc is induced from day 7 onward and GGTTCCAAGGATAACATCAAACA CATTTGGATGTCACATGGCTTA Alcam protein, as marker for the heart region in early embryos (Murakami et al., 2007) , could not be detected before day 10. Thus, the marker genes indicate the proper differentiation of the EBs. In addition, we analyzed the expression of direct Bmp target genes Id1, Id3, and Smad6 as well as the phosphorylation status of the Bmp signaling mediator Smad1. The qPCR analysis of the expression of Bmp marker genes indicated an induction of endogenous Bmp signaling activity at day 5 (Fig. 1D ). EGFP protein itself could also be detected in undifferentiated BREESCs and was subsequently induced from day 5 onward. Low Smad1 phosphorylation could be detected already in undifferentiated BRE-ESCs. It was not detected at day 3 and 5 but was induced again from day 7 onward (Fig. 1B) . The somewhat delayed detection of proteins, in particular of the phosphorylated Smad1, might be due to lower sensitivity of Western blots that is also highly dependent on the respective antibody. Additionally, the phosphorylation of Smad1 represented the actual signaling status of the cells, whereas the expressed EGFP as well as the expression of Brachyury documented the activity of Bmp signaling over a longer time period. Altogether, EGFP expression nicely correlated with the transcriptional levels of Bmp target genes and, in particular in respect to the biphasic Bmp activity profile, with a consistent phosphorylation status of Smad1, confirming that EGFP expression indeed indicates endogenous Bmp signaling activity as had already been shown in vivo.
Quantification of EGFP Expression
To quantify the EGFP expression over the course of differentiation, we tested whether the EGFP expression can be measured directly in cell lysates. To ensure sufficient EGFP expression, 25 EBs from day 7 of differentiation were pooled for each measurement and the EGFP expression was quantified using a Tecan Infinite M2000 plate reader (excitation: 485 nm, emission: 535 nm). In a serial dilution experiment the relative EGFP amount nicely correlated with the relative protein amount ( Fig. 2A) , thereby allowing a linear slope regression (R 2 ¼ 0.9968).
In addition, different methods for standardization were tested. Figure 2B shows the correlation between cell viability, determined by CTB measurements and the protein amount within the lysate using the absorption at 280 nm (OD 280 ). Because there were no significant differences applying either of the 2 methods, standardization was further carried out using the protein amount determined via OD 280 in all subsequent experiments. In the following experiments, the cultures were evaluated microscopically before lysate preparation and lysates that displayed a clear reduction of the protein concentration indicating unspecific, general toxic effects, were excluded from further analysis.
As an alternative experimental approach, we analyzed EGFP expression via FACS. Here, we could verify our previous results. In undifferentiated ESC cultures, already 15% EGFP-positive cells could be detected. However, no EGFP expressing cells were found at day 3 of differentiation, whereas EGFP expression was induced again at day 5 and reached its maximum at day 7, with over 40% of the cells being EGFP-positive ( Fig. 2C and 2D ). At later stages roughly 30% of the cells maintained a high level of EGFP expression. In addition, the FACS analysis revealed that the absolute amount of EGFP expression varied over a wide range among EGFP-positive cells indicating the formation of distinct cell populations. Applying EGFP measurements in cellular lysates, we obtained comparable results. Significant EGFP expression was induced between day 5 and 7 of differentiation. Again, the highest activity could be found between day 7 and 10, whereas in later stages of differentiation the EGFP expression dropped again (Fig. 2E) . The discrepancy between FACS and lysate measurements of EGFP expression, especially seen on day 3, might be explained with the autofluorescence from dead cells which are commonly found during the differentiation process. In contrast, FACS analysis allowed to gate for living cells, thereby reducing potential, unspecific autofluorescence.
In sum, the analysis of EGFP expression by Western blot, qPCR, FACS, and fluorescence measurements in cellular lysates strongly correlated and confirmed a differentiation-dependent expression of the EGFP transgene. Importantly, FACS analysis of BRE-ESCs allowed the quantification of the number of EGFPpositive cells as well as the identification of cell populations with distinct EGFP expression levels, whereas the general EGFP expression could easily be determined by fluorescence measurement in cellular lysates. The latter being particularly interesting, because it greatly facilitates the analysis and quantification of effects of chemicals on cellular differentiation and Bmp signaling activity.
Stage-Dependent Inhibition of EGFP Expression and Cardiomyocyte Differentiation by a Bmp Antagonist
To confirm the Bmp dependence of the EGFP expression, we analyzed the effect of the specific Bmp inhibitor LDN193189 on EGFP expression and cardiomyocyte differentiation. LDN193189 was recently shown to interfere with the activity of Bmp type I receptors with even higher specificity than the previously identified inhibitor Dorsomorphin (Vogt et al., 2011) . Continuous exposure of differentiating BRE-ESCs to various LDN193189 concentrations revealed a significant reduction of EGFP expression and a dramatic reduction of cardiomyocyte differentiation already at 5 nM (Fig. 3A) , thereby confirming the specificity for EGFP expression as a Bmp target gene as well as the importance of Bmp signaling for the differentiation of mesodermal derivatives. Similar experiments with SB431542, a specific inhibitor for Tgfb signaling via Smad2 and 3, resulted in impaired cardiac differentiation, but did not significantly reduce EGFP expression ( Supplementary Fig. S1 ). We further could verify inhibition of Id1 and Smad6, 2 direct Bmp target genes, by LDN193189 at the mRNA level (Fig. 3B) . The mRNA of these 2 target genes was similarly downregulated in a comparable dose-dependent manner as EGFP. Additionally, we could detect repression of mesodermal (Gata4), endodermal (Afp), and the endothelial cell lineages (CD31/ Pecam1), whereas neural differentiation seemed to be stimulated as indicated by the enhanced expression of the neural marker gene Map2 (Fig. 3B) . To further confirm the time point of Bmp induction within the differentiation process, we applied the inhibitor LDN193189 at 5 nM during different time periods (Fig. 3C) . Interestingly, this inhibitor does not affect differentiation when applied only between day 0 and 3: neither EGFP expression nor the formation of beating cardiomyocytes was reduced. In contrast, the differentiation is efficiently impaired when the inhibitor is applied continuously for 7 days. Moreover, exposure between day 3 and 7 was sufficient to elicit the strong inhibitory effect of LDN193189 on EGFP expression and cardiomyocyte formation (Fig. 3C) . To further narrow down the critical time frame, we exposed cells to 5 nM LDN193189 from days 0, 3, 4, 5, 6 or 7 of differentiation onwards (Fig. 3D) . LDN193189 did not affect EGFP expression when applied later then day 3 of differentiation ( Fig. 3D) . Although the expression of EGFP peaked at day 7 (Fig. 2D ), we were unable to chemically interfere with the induction of EGFP expression after day 3. So, the presence of LDN193189 during the short time window between day 3 and 4 FIG. 3. Dose-dependent inhibition of EGFP expression and cardiomyocyte differentiation by LDN193189. A, Dose-dependent effect of LDN193189 on EGFP expression (green bars) and the differentiation of cardiomyocytes (red bars). Contracting areas were no longer detectable at 5nM LDN193189 but significant EGFP expression could still be found in cell lysates. B, qPCR analysis of LDN193189 effects on the differentiation process at day 7 of differentiation. The expression of the indicated marker genes were standardized against Gapdh expression and normalized against the untreated control. C, Determination of the inhibitory effect of LDN193189 on EGFP expression at day 7 (green bars) and cardiomyocyte differentiation at day 10 (red bars) after exposure from day 0-7, 0-3, and 3-7, respectively. D, The effect on EGFP expression (green bars) and cardiac differentiation (red bars), with significant reduction of both endpoints with 5 nM LDN193189.
of differentiation is required to inhibit EGFP expression in differentiating BRE-ESCs. To confirm this, a dose-response experiment was performed restricting the exposure of differentiating BRE-ESCs against LDN193189 to the time window of day 3 to day 4 of differentiation ( Fig. 3E ). This short exposure time resulted in a reduction of EGFP expression that was comparable with the inhibition after continuous exposure from day 0 onward. Similarly, the differentiation into cardiomyocytes could be effectively inhibited by 5 nM LDN193189 after transient exposure between day 3 and 4, although the inhibitory effect of LDN193189 was somewhat less effective ( Fig. 3A and 3E) . Together, these results indicate that inhibition of EGFP expression is highly dependent on a specific time window that correlates with mesoderm induction. After the induction of mesoderm and concomitant EGFP expression, LDN193189 can no longer interfere with EGFP expression. The relatively long half-life of EGFP protein (Corish and Tyler-Smith, 1999 ) might contribute but can hardly explain this effect on its own. Importantly, EGFP expression and cardiomyocyte differentiation again correlated nicely. Further, our qPCR results suggest that EGFP-positive cells might contribute to the endodermal and endothelial cell lineages (Fig. 3B) .
Characterization of EGFP-Positive Cells
To confirm the identity of the EGFP-positive cells as being distinct from the beating cardiomyocytes, we analyzed day 10 EBs using confocal microscopy after staining for MF20, that is, a marker for myosin heavy chain in cardiac and skeletal muscle. As expected the 2 cell types are in close proximity, but none of the EGFP-positive cells were positive for MF20 (Fig. 4A, upper  panel) .
The net-like structures that were formed by the EGFPpositive cells at day 10-12 of development indicated that these cells might develop into endothelium. Thus, we analyzed the expression of early endothelial markers, in particular vascular endothelial growth factor receptor 2 (Flk1/Vegfr2) and CD31, in immunohistochemical studies (Fig. 4B) . Indeed, some of the EGFP-positive cells forming the net-like structures simultaneously expressed Flk1 and CD31. We then tested whether the endothelial cells are functional and display the typical increased metabolism of Ac-LDL that can be detected after addition of Ac-LDL conjugated to the carbocyanine dye Dil (DiI-Ac-LDL) to the medium (Voyta et al., 1984) . DiI-Ac-LDL was added for 4 h and the cells analyzed by confocal microscopy. As can be seen in the lower panel of Figure 4A , differentiating EBs developed cells that took up DiI-Ac-LDL and some of these cells were also positive for EGFP supporting the assumption that some of the EGFP-positive cells might indeed form functional endothelial cells.
Next, FACS was used to confirm that some of the EGFPpositive cells are committed to endothelial lineage. As shown in Figure 4C , approximately one-half of the cells at day 7 and 10 of differentiation expressed CD31. In addition, a significant proportion of the cells were EGFP-positive at day 7 (44%) and day 10 (34%). Most importantly, almost one-half of the CD31 positive cells were also found positive for EGFP at day 7 and vice versa. In addition, we used FACS to separate EGFP-positive from EGFPnegative cells and compared these 2 cell populations by qPCR analysis. Thereby we confirmed that purified EGFP-positive cells displayed increased levels of Flk1 as well as Afp mRNA compared with the EGFP-negative cells, although the increase in expression with respect to Flk1 was rather low (Fig. 4D) . Thus, a significant number of the EGFP-positive differentiated toward endodermal and endothelial fate. Our results indicate that the EGFP reporter might be suitable for the analysis of vascularization and angiogenesis in vitro.
Time-Dependent Effects of VPA and CHIR99021 on EGFP Expression and Cardiomyocyte Differentiation
We compared the activity of valproic acid (VPA) and the specific Gsk3ß inhibitor CHIR99021 on the expression of EGFP and cardiomyocyte differentiation. We first tested the activity of 100 mg/ml VPA during different time periods, a concentration that has been described before to inhibit cardiomyocyte differentiation efficiently (Genschow et al., 2004) . As expected, VPA efficiently inhibited EGFP expression and cardiomyocyte differentiation when applied for 7 days (Fig. 5A) . However, the inhibition was similar if the cells were exposed to VPA for the first 3 days of differentiation only. In contrast, exposure to VPA after day 3 did not significantly affect EGFP expression or cardiomyocyte differentiation. Thus, VPA exposure during the early phase of differentiation is necessary and sufficient for VPA to exert its inhibitory effects, indicating that VPA interferes with differentiation processes before Bmp signaling is induced.
We compared the time-dependent activity of VPA with the specific chemical Gsk3ß inhibitor CHIR99021. Gsk3ß is a central component of the Wnt signal transduction pathway and inhibition of Gsk3ß is mimicking active Wnt signaling in many aspects. Here, we were able to demonstrate that increased Wnt signaling also interferes with the differentiation of cardiomyocytes as well as EGFP expression. Interestingly, similar to VPA, inhibition of Gsk3ß by CHIR99021 for 3 days sufficed to reduce EGFP expression, whereas treatment from day 3 of differentiation onward had no significant effect on the general EGFP expression level (Fig. 5B) . However, already at day 7, we observed a change in the morphology of the EGFP-positive cells that clustered over the entire outgrowth (Fig. 5D ). This suggested altered cell fate through increased Wnt signaling at later stages of differentiation that was not seen after VPA treatment (Fig. 5C ). In addition, CHIR99021 treatment impaired cardiac differentiation at all time windows tested. Thus, in comparison with VPA treatment, the stimulation of Wnt signaling by inhibition of Gsk3ß activity had some similar but also certain distinct effects on BRE-ESC differentiation. These results imply that VPA and CHIR99021 exert overlapping but also distinct activities, a result that further emphasizes the potential value of the BRE-ESCs in the analysis of the molecular mode of action of teratogenic substances. In addition, morphological evaluation of the EGFP-positive cells might provide an additional endpoint for the assessment of potentially toxicological effects. Our results also show that EGFP expression and cardiomyocyte differentiation do not necessarily correspond. Instead, EGFP expression has been established as an independent endpoint. Overall, application of BRE-ESCs enable for comparative analysis and characterization of the mode of action of chemical substances during the process of tissue differentiation.
Comparison of the Dose Response of Known Teratogenic Substances on EGFP Expression and Cardiomyocyte Differentiation
Finally, we wanted to compare the dose dependence of the effects of known teratogens on the expression of EGFP with the classical endpoint of cardiomyocyte formation. We selected retinoic acid (RA), 6-aminonicotinamid (ANA), and VPA because these substances have been well characterized in the classical EST and have been shown to act via distinct mechanisms. We performed dose-response experiments in which we determined the differentiation into cardiomyocytes on day 10 and the expression of EGFP on day 7 (Fig. 6A-C) . For all 3 teratogens, both endpoints were significantly affected at comparable concentrations that correlated with previously described ID 50 values from classical EST studies (ID 50 for VPA: 50 6 8 mg/ml, RA: 0.8 6 0.7 ng/ml, and ANA: 1.0 6 0.3 mg/ml) (Genschow et al., 2004 ). Thus for the tested substances, the impairment of differentiation can be evaluated with both methods, whereas the EGFP method provides the advantage that the measurements can be done 3 days earlier.
DISCUSSION
Here, we describe the characterization of an ESC line isolated from mice carrying a transgenic EGFP reporter gene under control of a BRE as tool for the in vitro analysis of Bmp-dependent for 3 days, 7 days or during day 3-7 of differentiation. At day 7, EGPF levels were quantified by fluorescence measurements in cellular lysates (green bars) and cardiomyocyte differentiation was assessed microscopically at day 10 (red bars). The microscopic appearance of the treated cells at day 7 is depicted in C and D for VPA (C) and CHIR99021 (D), respectively (brightfield in the upper panel, EGFP fluorescence of the same EB outgrowth in the lower panel).
processes and the characterization of the teratogenic activities of chemical compounds. The transgene has been previously characterized in vivo as a reliable tool to follow Bmp signaling in vivo (Monteiro et al., 2008) . Bmp signaling contributes to the formation of various organs and tissues in the course of vertebrate embryogenesis (Zhao, 2003) and, as expected, EGFP transgene expression broadens at later stages of development. We show that BRE-ESC reporter cells reproducibly differentiated into cardiomyocytes using the hanging drop method with kinetics comparable to the ESC line D3 described earlier (Seiler and Spielmann, 2011) . Low levels of EGFP expression were already detectable in pluripotent BRE-ESCs before induction of differentiation correlating with the observation that Bmp target genes of the inhibitor of differentiation (Id) family are expressed in undifferentiated ESC cultures in the presence of fetal calf serum (Ying et al., 2003) . Within 10 days, we observed robust cardiac differentiation as well as significant expression of EGFP, with almost one-half of all cells being EGFP-positive already after day 7 (Figs. 2 and 4) . The differentiation-dependent expression of EGFP correlated well with the expression of known Bmp target genes and pSmad1 levels in the developing EBs coinciding with the time of mesoderm formation (Winnier et al., 1995) , as well as with EGFP expression observed in the transgenic mice in vivo (Monteiro et al., 2008) . Similar as in the reporter mice, the EGFP-positive cells formed different cell types during in vitro differentiation, including endodermal and endothelial cells.
After 10 days of differentiation, immunohistochemistry indicated the formation of EGFP-positive net-like structures expressing the endothelial markers CD31 and Flk1 (Fig. 4) . These results were confirmed in FACS analyses that verified the presence of EGFP/CD31 double-positive cells. In addition, a subset of the CD31-positive cells was EGFP-positive and the mRNA levels of endothelial marker genes were subtly increased in the EGFP-positive cell population. This is in line with the observation that the expression of EGFP in vivo is confined to a specific subset of endothelial cells during the specification of stalk and tip cells probably due to the inhibitory effect of Notch signaling (Moya et al., 2012) . A discrepancy between nuclear pSmad1/5/8 and EGFP-positive cells was also observed in vivo that could reflect the relatively long half-life of EGFP that interferes with a direct correlation with the highly dynamic changes in Smad phosphorylation (Corish and Tyler-Smith, 1999) .
Recently, an in vitro model based on gene expression analysis has been described to characterize the effects of chemical teratogens on endothelial differentiation (Festag et al., 2007) , generating similar results as obtained in the classical EST. We tested our system by applying a set of well-characterized chemical teratogens in dose-response experiments and showed that the effects of these compounds on EGFP expression at day 7 correlated with the effects on cardiac differentiation at day 10 of differentiation ( Fig. 6) . Similar results were obtained using endothelial marker genes (Festag et al., 2007) . However, it remains unclear whether this assay can actually extend the applicability domain of the EST. To this end it has to be analyzed in detail in future studies applying tissue-specific teratogenic substances. On the other hand, analysis of high-throughput screening data originating from ToxCast compounds strongly suggests that vascular development is a suitable endpoint for the assessment of developmental toxicity and the characterization of modes of actions for teratogenic compounds . Taken together, the BRE-ESCs provide a suitable tool for the analysis of both cardiomyocyte and endothelial cell differentiation.
Experiments with the specific Bmp inhibitor LDN193189 and the TGFb inhibitor SB431542 supported the specificity of the reporter construct but also revealed additional aspects of cardiac differentiation (Fig. 3 and Supplementary Fig. S1 ). LDN193189-induced neural (ectodermal) cell fate at the expense of mesendodermal differentiation. These effects were expected, because Bmp activity is required in the cellular differentiation of mesendodermal tissues and subsequent mesodermal differentiation (Van Vliet et al., 2012) . Conversely, inhibition of Bmp signaling is essential for the determination of neural cell fate in vivo (Bier et al., 2011) . The strongest effects of LDN193189 treatment were observed on endodermal marker genes and qPCR analysis following cell sorting indicated that EGFP-positive cells were partially endodermal (Fig. 4) . As discussed by Rana (2013) , differentiation of the cardiac mesoderm in vivo depends on the underlining endodermal cell layer that expresses Bmp protein thereby inducing the expression of cardiac specific transcription factors such as Nkx2.5 and Gata4. In vitro, the endodermal gene Sox17 acting downstream of the early endodermal marker Afp was found to be required for the differentiation of primitive mesoderm into cardiac mesoderm (Liu et al., 2007) . In our culture system, cardiomyocytes are EGFP-negative but the EGFP-positive cells were frequently found in the vicinity of beating cardiomyocytes (Fig. 4) . Thus, it will be interesting to determine whether these cells are equivalent to the endodermal cells that control cardiac development in vivo. The induction of mesodermal fate in BRE-ESCs took place between day 3 and 4 of differentiation, and this was also found to be the most effective time window for LDN193189 to inhibit EGFP expression and the formation to both endoderm and mesoderm.
Based on our results, microscopic evaluation of EGFP-positive cells offers useful additional information to reveal the mode of action of certain chemicals (Fig. 5) . For example, the Wnt agonist CHIR99021, an inhibitor of phosphorylation and subsequent degradation of b-catenin through Gsk3b, displayed a time-dependent effect on EGFP expression. When cells were treated for the first 3 days or the entire time period of 7 days, the inhibitor markedly reduced EGFP expression and cardiac differentiation. Interestingly, when applied from day 3 onward, CHIR99021 alters cell fate noticeable in a changed morphology of EGFP-positive cells, which then cluster all over the EB outgrowth, indicating that CHIR99021 exerts distinct effects depending on the differentiation status. It also points to the independence of the EGFP endpoint, as cardiac differentiation can be impaired without loss of EGFP expression, an effect that was also seen with the specific TGFb inhibitor SB431542 ( Supplementary Fig. S1 ).
These analyses of small chemical antagonists of BMP and Wnt signaling suggest that the BRE-ESC might also serve as a valuable tool for the identification and characterization of chemical modulators of Bmp or Wnt activity in the frame of biomedical research. Cell lines as well as phenotypic screens in zebrafish have already been successfully applied for screening substances that specifically activate or inhibit these signaling pathways (Rennekamp and Peterson, 2015; Vrijens et al., 2012) . The BRE-ESCs provide a distinct differentiation-dependent cellular context, are compatible with high-content and highthroughput screening approaches and rely on the endogenous, differentiation-dependent regulation of the BMP pathway. Future studies have to show if they can have a significant impact on these kinds of studies.
Similar to CHIR99021, VPA also has an effective time window between day 0 and 3, pointing to a related mode of action of both compounds. Indeed, VPA has been proposed to inhibit Gsk3b, mimicking active Wnt signaling (Chen et al., 1999) , but also to act as histone deacetylase antagonist (Wiltse, 2005) . Bmp and Wnt signaling are both essential for mesoderm induction during early embryonic (Loebel et al., 2003; Winnier et al., 1995) and subsequent cardiac development (Van Vliet et al., 2012) . Interestingly, Bmp and Wnt signaling pathways can directly interact because Gsk3b directly phosphorylates and inhibits Bmp-specific Smads (Fuentealba et al., 2007) . In contrast to CHIR99021, however, VPA did not affect EGFP expression or cardiac differentiation at later stages of differentiation pointing to a distinct mode of action of VPA. The analysis of additional teratogens, in particular RA and ANA, demonstrated that EGFP measurement allows the characterization of teratogens with different molecular mode of actions (Fig. 6) . RA is known to act as ligand for RA (RAR) and retinoid X receptors (RXR) which both can heterodimerize and bind to regulatory elements in RAresponsive genes. Exogenous RA can interfere with the endogenous RA signaling leading to teratogenic effects (Horton and Maden, 1995; Mark et al., 2006) . In contrast, ANA is thought to interfere with the pentose phosphate pathway by inhibiting glucose-6-phosphate dehydrogenase (Tyson et al., 2000) .
Finally, our results also implicate BRE-ESCs as a valuable tool for high-throughput analysis of potential teratogenic compounds in combination with high content imaging. Such an approach might allow EGFP measurement in combination with the evaluation of the morphology and the cardiac differentiation of individual EBs at the same time.
There are multiple ways to analyze the effects of chemical teratogens on signaling cascades. For instance, transfecting reporter constructs directly into ESC and evaluating its activity after exposure with teratogenic compounds, as has been described for the ReproGlow assay (Uibel et al., 2010) . However, it seems important to keep in mind that the activity of artificial reporter gene constructs might be affected by its genomic integration site and not necessarily reflect corresponding in vivo activities (Wilson et al., 1990) . This problem might be partially solved with the establishment of cell lines derived from transgenic animals for which in vivo information relating to the onset and tissue-specific expression of the transgene is available. Reporter mouse lines have been already established for various evolutionarily conserved signaling pathways (eg, Wnt, Notch) known to be involved in a plethora of developmental processes and in tissue homeostasis (Maretto et al., 2003; Nowotschin et al., 2013) .
In summary, we demonstrated that BRE-ESCs represent a versatile tool to assess Bmp activity in ESC differentiation and the analysis of teratogenic effects of compounds in vitro using an established protocol for cardiomyocyte differentiation. Because Bmp signals play a pivotal role in the formation of various organs these cells might also be used to address other differentiation processes, including neurogenesis or osteogenesis, if specific differentiation protocols can be applied.
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